Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited reported a flattish performance in Q3 FY26, with revenue at INR 73 crores. Despite this, PAT grew by 10% year-on-year to INR 12.5 crores, and PAT margins improved by 180 basis points to 17.1%. EBITDA for the quarter stood at INR 16.7 crores, translating to an EBITDA margin of 22.7%, reflecting operational resilience.

For the nine-month period of FY26, the company demonstrated resilient performance with revenue growing 6% year-on-year to INR 223 crores. EBITDA increased by 5% year-on-year to INR 50.3 crores, maintaining margins at 22.6%. PAT for the nine-month period stood at INR 35.9 crores, marking a 12.5% year-on-year growth with margins at 16.1%.

The company underwent a strategic recalibration of its field operations and leadership team, including the appointment of a new COO and CFO. While these changes led to some near-term disruption and elevated attrition, management expects the benefits to start reflecting from Q4 FY26. The overall intent is to improve the long-term growth engine of the company by enhancing commercial effectiveness and team stability.

Jagsonpal Pharmaceuticals Limited provided for an additional past service cost of INR 2.1 crores as a one-time^📎 exceptional item^📎 during Q3 FY26, in anticipation of the new labor code. Management clarified that while there will be some restructuring of salaries across all levels, the ongoing impact on employee costs is expected to be very limited. The state rules for the code, effective from November 21, are still pending notification, expected by February or March.

The company's free cash balance reached INR 176 crores, increasing by INR 15.2 crores in Q3, reflecting strong operational discipline. Management expressed a strong intent for disciplined and accretive M&A, similar to the successful Yash Pharma acquisition. However, they noted that current asset valuations are high, making it challenging to find suitable targets. If cash cannot be efficiently deployed, the company would consider returning it to shareholders.

The Indian pharmaceutical market (IPM) grew at about 8%, primarily driven by 5-5.5% price growth, with muted volume growth. Jagsonpal's relevant market (RPM) grew slower at 3-3.5%. The company expects future growth to be driven 50% by price increases and new product/SKU introductions, with the remaining from volume growth. The portfolio mix is roughly 35-40% acute and the rest semi-chronic.

Management is actively working to improve salesforce productivity, which is currently below peer group levels, aiming for higher double-digit growth. Efforts include strategic repositioning of brand teams to focus on high-potential brands and optimizing field deployment. The company also rationalized some very small SKUs that were tying up capital, with an estimated revenue impact of 1.5-2% of the top line, to focus on building larger brands.